In conclusion, we demonstrated that Foxa2 ameliorates hepatic steatosis in NAFLD and suppresses NF-κB/IKK signaling pathway activation in OA-stimulated HepG2 cells, thus presenting a new therapeutic target for NAFLD treatment. Here, NFKB1 is linked to fatty liver disease.